Tenboron is a Helsinki-based drug development company that specializes in boron neutron capture therapy (BNCT). BNCT is a targeted radiation therapy where boron-10 (10B) atoms are selectively delivered to tumors and irradiated with epithermal neutrons. This causes a nuclear reaction resulting in the production of particles that effectively kill cancer cells at the site of boron accumulation.

Tenboron's lead boron carrier, a high concentration of boron atoms with an antibody targeting unit, is designed to specifically target cancerous cells, addressing one of the challenges of BNCT. Founded in 2010, Tenboron has been inspired by successful trials conducted at the Helsinki University Central Hospital and the VTT nuclear reactor facility FiR-1. As a privately held SME with over 500 shareholders, Tenboron receives financial support from Business Finland.

The company has a strong team led by Dr. Timo Veromaa as Chairman and Mr. Juha Jouhki as Chief Executive Officer.

They work closely with partners such as Glykos Finland Ltd. Tenboron is committed to developing novel boron carriers for BNCT that have the potential to be cost-effective, require low treatment sessions, and minimize damage to healthy tissues. By combining innovation, expertise, and a collaborative approach, Tenboron aims to make a significant impact in the field of cancer therapy.

To learn more about their groundbreaking work, visit their website or reach out through their contact information